Chemours (NYSE:CC) Stock Gets Price Target Cut from Truist Financial

Chemours (NYSE:CC) had its target price decreased by Truist Financial from $20.00 to $18.00 in a report released on Wednesday morning,Benzinga reports. Truist Financial currently has a buy rating on the specialty chemicals company’s stock.

A number of other research analysts have also weighed in on the stock. Royal Bank Of Canada lowered shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target on the stock. in a research note on Tuesday, October 13th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $16.00 price target on shares of Chemours in a report on Friday, October 9th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 10th. BMO Capital Markets dropped their price objective on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 13th. Three equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $17.45.

Chemours Trading Down 0.2%

NYSE:CC traded down $0.03 during mid-day trading on Wednesday, hitting $12.72. The company had a trading volume of 3,698,087 shares, compared to its average volume of 2,310,033. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The firm has a market cap of $1.91 billion, a P/E ratio of -12.47 and a beta of 1.47. The business’s fifty day moving average is $13.96 and its two-hundred day moving average is $18.22.

Chemours (NYSE:CC) last announced its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 78.76%. The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same period last year, the firm earned $0.40 EPS. Chemours’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, research analysts expect that Chemours will post 0.82 earnings per share for the current year.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Monday, November 16th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $0.35 annualized dividend and a dividend yield of 2.8%. Chemours’s payout ratio is -34.31%.

Insider Buying and Selling

In related news, CEO Denise Dignam acquired 3,378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was bought at an average price of $14.95 per share, with a total value of $50,501.10. Following the acquisition, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. This represents a 1.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Calderon Gerardo Familiar bought 1,935 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. This represents a 3.42% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Chemours

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Chemours in the second quarter valued at $477,769,000. Wolf Hill Capital Management LP acquired a new stake in Chemours in the 2nd quarter valued at about $59,698,056. Jefferies Financial Group Inc. grew its holdings in Chemours by 251.8% during the third quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock worth $37,210,000 after purchasing an additional 1,962,523 shares during the period. Bank of New York Mellon Corp bought a new position in Chemours during the second quarter worth about $33,353,000. Finally, Legal & General Group Plc acquired a new position in Chemours during the second quarter worth approximately $28,400,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions aimed at managing heat in AI data centers, with the company touting improved efficiency and lower water use. The product could help it benefit from growing data-center demand. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Barclays maintained its Hold rating. Other analyst views are mixed, while UBS lowered its price target to $15 and kept a Neutral rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Zacks Research downgraded CC from Hold to Strong Sell, adding to concerns about analyst sentiment. Zacks Research rating information
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers, covering purchases from February 20 through August 4, 2026. The suit alleges securities-law violations, including claims related to 2026 EBITDA guidance and refrigerant sales pulled forward by customer prebuying; these allegations have not been proven. Investors have until December 7 to seek lead-plaintiff status. The repeated alerts concern the same case, rather than separate lawsuits. Article: Lawsuit deadline and allegations regarding 2026 EBITDA guidance

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.